Use FDA guidance as the rulebook for medical device submissions, and use the NIST Cybersecurity Framework as the playbook for running security every day. The FDA tells device makers what regulators expect before and after a product reaches patients. NIST helps teams organize the work so security does not become a drawer full of scary PDFs.
TLDR: FDA guidance is medical device specific. NIST CSF is security program specific. A maker of 500 connected infusion pumps might use FDA guidance to prove the pumps were built and tested safely, then use NIST to track patching, alerts, and recovery across hospitals. If 12% of devices run outdated firmware, NIST helps find and fix the pattern, while FDA guidance helps show the fix is safe and documented.
Two tools, two jobs
Think of FDA guidance and NIST CSF like a seat belt and a road map.
- FDA guidance asks, “Is this medical device safe and secure enough for patient use?”
- NIST CSF asks, “Does the organization manage cyber risk in a sane way?”
Both matter. They just do different things.
The FDA cares about the device, its software, its updates, and its real-world risk to patients. NIST cares about structure. It helps teams group work into buckets like governance, asset tracking, protection, detection, response, and recovery.
Honestly, it feels like security teams sometimes get handed both and told, “Just comply.” Great. Now the coffee is cold.
The trick is simple. Use FDA guidance for what must be proven for the device. Use NIST CSF for how the company runs the security process.
Image not found in postmetaWhat the FDA guidance wants
The FDA guidance is built around medical risk. That makes sense. A hacked fitness tracker is annoying. A hacked insulin pump is a very different story.
The FDA expects manufacturers to think about cybersecurity from the start. Not at the end. Not two days before submission. Not when someone says, “Wait, does this thing have Bluetooth?”
Common FDA expectations include:
- Secure design: Build security into the device early.
- Threat modeling: Ask how attackers might abuse the device.
- Software bill of materials: List software parts, libraries, and components.
- Risk assessment: Connect cyber issues to patient safety.
- Security testing: Test for weakness before launch.
- Patch planning: Explain how fixes will be delivered.
- Labeling: Tell users what security steps they must take.
- Postmarket monitoring: Watch the device after release.
The big FDA idea is this: a device is not “done” when it ships. It needs support. It needs updates. It needs monitoring. Yes, even if the hardware looks cute and harmless.
What NIST CSF wants
NIST CSF is broader. It is not written only for medical devices. Banks use it. Energy companies use it. Hospitals use it. Device makers can use it too.
NIST CSF 2.0 is organized around major functions:
- Govern: Set roles, policies, and risk goals.
- Identify: Know your assets, systems, data, and suppliers.
- Protect: Add safeguards like access control and encryption.
- Detect: Spot strange activity fast.
- Respond: Act when something goes wrong.
- Recover: Restore systems and learn from the mess.
NIST is less like a checklist for one device. It is more like a gym plan for the whole company. It helps build muscle. Boring muscle, maybe. But useful muscle.
For device security, NIST helps answer questions like:
- Who owns cybersecurity risk?
- Which devices are connected?
- Which suppliers create risk?
- How fast are alerts reviewed?
- How are patches approved?
- Who calls customers during an incident?
The quick comparison
| Area | FDA Guidance | NIST CSF |
|---|---|---|
| Main focus | Medical device safety and effectiveness | Cyber risk management program |
| Best for | Device design, submissions, safety cases | Policies, controls, operations, maturity |
| Audience | Manufacturers and regulators | Security, risk, IT, and business teams |
| Output | Evidence for a secure medical device | A repeatable security management model |
| Timing | Before and after market release | All the time |
The FDA says, “Show me the device will not put patients at avoidable cyber risk.” NIST says, “Show me your organization can manage cyber risk without panic spaghetti.”
Where they overlap
There is plenty of shared ground. Both care about risk. Both want documentation. Both expect action, not vibes.
They overlap in areas like:
- Asset management: You cannot protect what you cannot find.
- Risk analysis: Not all bugs are equal.
- Access control: Keep random people out.
- Monitoring: Watch for trouble.
- Incident response: Plan before the alarm rings.
- Recovery: Get back to safe operation.
- Supplier risk: Your vendor’s problem can become your recall.
The overlap is good news. Work done for NIST can support FDA expectations. Work done for FDA can strengthen your NIST profile. This is not double work if planned well.
A simple user case
Meet MediPump Co., a fictional maker of smart infusion pumps.
The pumps connect to hospital networks. They receive drug library updates. They send status data. They also run software with third-party components.
For FDA purposes, MediPump Co. must show:
- The pump has secure boot.
- Updates are signed and checked.
- Threat modeling was done.
- Known vulnerabilities were reviewed.
- The SBOM is complete.
- Patient safety risks were assessed.
For NIST purposes, the company must manage the bigger system:
- Track all released pump versions.
- Monitor new software vulnerabilities.
- Assign owners for patch decisions.
- Alert hospitals when action is needed.
- Measure patch adoption rates.
- Practice incident response drills.
Here is a practical metric. MediPump Co. finds that 18% of deployed pumps are one firmware version behind. That is not just a tech fact. It is a risk signal. NIST helps manage the signal. FDA-style documentation helps prove that the update process is safe for patients.
SBOMs: useful, but not magic
The FDA pays close attention to the software bill of materials. An SBOM lists what is inside the device software. Think of it like an ingredient label for code.
This is great in theory. In practice, it can be messy.
It drives me crazy when SBOM files arrive as mystery spreadsheets with missing versions and weird names. One component is called “crypto lib.” Another is called “final final build.” Cool. Very calming.
A good SBOM should include:
- Component names
- Version numbers
- Supplier details
- Known vulnerabilities
- Update status
- End-of-support risks
FDA guidance pushes manufacturers to provide this level of clarity. NIST helps teams keep it useful over time. Without process, an SBOM becomes a dusty artifact. With process, it becomes a warning system.
Premarket vs postmarket
FDA guidance has a strong premarket angle. Before a device is cleared or approved, manufacturers must show security planning and evidence.
But security does not stop at launch. New flaws appear. Attack methods change. Old libraries expire. Hospital networks get weird. Someone plugs in something they should not have plugged in.
Postmarket work includes:
- Vulnerability intake
- Patch testing
- Customer alerts
- Coordinated disclosure
- Risk re-assessment
- Field updates
NIST fits nicely here. It gives structure to the daily grind. Who reviews alerts? How often? What happens if a vulnerability is rated critical? How fast can a fix ship? Who signs off?
Which one should you use first?
If you build medical devices, start with FDA expectations. They are tied to regulatory success. No one wants a submission delayed because the cybersecurity section looks like a napkin sketch.
Then map that work to NIST CSF. This creates a clean bridge between product teams and security teams.
A useful workflow looks like this:
- Define the device use case. What does it do? Where is it used?
- List the assets. Software, data, cloud services, interfaces, users.
- Run threat modeling. Find abuse paths.
- Rate patient risk. Tie cyber harm to clinical impact.
- Build controls. Authentication, encryption, logging, update checks.
- Test hard. Scan, fuzz, review, and penetration test.
- Create the SBOM. Keep it accurate.
- Plan monitoring. Track vulnerabilities after release.
- Map to NIST. Show how the company manages the work.
The plain answer
FDA guidance is more specific, more clinical, and more tied to product approval. NIST CSF is broader, cleaner for management, and better for long-term operations.
Do not pick one and ignore the other. That is how gaps appear.
Best practice: Use FDA guidance to build and submit secure medical devices. Use NIST CSF to run the security program that supports those devices for years.
That combo keeps regulators happier. It keeps security teams saner. Most of all, it helps protect patients, which is the whole point.